A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

4220

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Elacestrant
DRUG: Anastrozole
DRUG: Letrozole
DRUG: Exemestane
DRUG: Tamoxifen

Sponsor

Stemline Therapeutics, Inc.